lung cancer

Overview

Lung cancer is a malignancy arising from the tissues of the lung, most commonly the bronchial epithelium and alveolar regions. It is a biologically heterogeneous cancer with major clinical subtypes, including non-small cell lung cancer and small cell lung cancer, and it is characterized by frequent genomic alteration, complex tumor microenvironment interactions, metastatic potential, and substantial treatment resistance. In recent biomedical literature, lung cancer is repeatedly described as one of the leading causes of cancer-related mortality worldwide, largely because many cases are diagnosed at advanced stages and because recurrence after therapy remains common.

From a mechanistic standpoint, lung cancer progression is shaped by multiple interacting processes, including immune evasion, ferroptosis resistance, programmed cell death pathways, radiation resistance, and signaling through pathways such as EGFR/FAK/STAT3, c-MYC-CHK1/CHK2, STAT1, and GPX4-related ferroptosis control. These features have made lung cancer a major focus for Targeted therapies, checkpoint inhibitor, biomarker discovery, radiotherapy optimization, and precision oncology approaches.

Focus of Latest Publications

Recent publications portray lung cancer as a central target for both translational and methodological research, with emphasis on prognosis, treatment resistance, early detection, and therapy optimization. Several studies highlighted the disease’s persistent lethality and clinical heterogeneity, noting that lung cancer remains highly fatal and is still the leading cause of cancer-related mortality worldwide. One roadmap-style review emphasized priorities in biology, therapeutic innovation, early detection, prevention, and interception, reflecting the broad research agenda surrounding this disease. Another study on real-world evidence used lung cancer as a case study to strengthen causal inference in observational research, underscoring the importance of robust analytic methods when evaluating treatment effectiveness outside clinical trials.

A major theme across the publications was treatment resistance and the tumor microenvironment. One review described exosome-mediated crosstalk between immune cells and the tumor microenvironment as a driver of immune evasion and therapeutic resistance in lung cancer. Related work on programmed cell death and ferroptosis emphasized that lung cancer biology is tightly linked to apoptosis, autophagy, and ferroptosis regulation. In this context, CRL2FEM1B was reported to use heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer, while another study found that NK92-derived exosomes induced ferroptosis in A549 cells through a miR-663a-SLC11A2 axis. A separate report described USP20 as governing tyrosine kinase inhibitor resistance through ferroptosis evasion by targeting GPX4, reinforcing the importance of ferroptosis-related pathways in drug response. Additional mechanistic studies implicated C1QBP-STAT1 signaling in activation of the c-MYC-CHK1/CHK2 axis and radioresistance, and another found that piperlongumine inhibited proliferation and migration of non-small cell lung cancer cells through the EGFR/FAK/STAT3 pathway.

immunotherapy and immune modulation were also prominent. One review noted that immunotherapy has improved lung cancer treatment in the recent decade, while another discussed biomarkers in the era of radioimmunotherapy. A study of immune checkpoint-refractory lung cancer reported that a triple combination of ATR inhibitor, anti-Gal-9, and anti-PD-1 showed superior efficacy, and a genome-wide association study examined genetic loci associated with immune-related adverse events in patients receiving PD-1/PD-L1 inhibitors. Additional work on cortisol-resistant CAR-NK cells suggested a strategy to overcome steroid-induced immunosuppression in lung cancer, and biomimetic proteolipid vesicles delivering small activating RNA were used to activate macrophage immunotherapy. These studies collectively reflect the growing role of checkpoint inhibitor, CAR-NK cells, macrophages, dendritic cells, cytotoxic T cells, and regulatory T cells in lung cancer research.

Several publications focused on diagnosis, staging, and early detection. A study on serum Raman spectroscopy used a continuous wavelet transformation-convolutional neural network approach to diagnose lung cancer from serum samples, while another investigated integrative fragmentomic and mutational signature profiling of plasma cfDNA for early lung cancer detection. Serum markers were also reviewed for diagnostic importance, and a study on pleural effusion characterization used 18F-FDG PET/MRI to detect pleural metastasis for staging. A multicentre observational cohort protocol, LUCIA, was designed to assess lung cancer risk factors and their impact, and another study emphasized that early and accurate detection remains a major clinical challenge. Low-dose computed tomography remains relevant in this context as a screening and early detection technology, even when not directly detailed in every publication.

Radiotherapy and surgical management were also represented. A machine-learning risk model was developed to predict radiation pneumonitis in lung cancer patients with interstitial lung disease, highlighting the need to manage toxicity in vulnerable populations. Another feasibility study used a transformer-based patient-agnostic tumor motion tracking model for radiotherapy, and a phase 2 trial evaluated high-dose reirradiation for in-field recurrent lung cancer. Surgical studies noted that surgery remains the main curative treatment for lung cancer patients, systematic lymph node dissection remains standard in early-stage disease, and postoperative outcomes were examined in relation to advanced age and risk factors. A national study addressed treatment-naïve lung cancer presenting with spinal metastases, and another examined the long-term impact of the COVID-19 pandemic on diagnosis and management in surgically resected patients.

The literature also included work on metastasis and special clinical settings. Brain metastasis biology was linked to CBX3+GPNMB+ circulating tumor cells and plasma CXCL12 in lung cancer and melanoma, while another study addressed spinal metastases as a first manifestation of lung cancer. A case report described RET-positive neuroendocrine lung cancer in pregnancy with placental metastases, emphasizing the rarity of lung cancer during pregnancy and the exceptional nature of placental spread. These reports reinforce the disease’s metastatic diversity and the need for individualized clinical assessment.

Finally, multiple studies explored emerging therapeutic platforms and biomarker technologies. Organoid-based work described construction and immunotherapy application of lung cancer organoids, and patient-derived malignant effusion organoids were used to guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms. Other studies investigated inhalable microbe-oncolytic virus consortia, high-entropy alloy–based radioimmunotherapy for lung metastases, nanoboxes for photo/chemodynamic therapy, paeoniflorin-copper nanoparticles, and ginsenoside derivatives targeting PRELID3B. These studies collectively illustrate how lung cancer serves as a testbed for precision medicine, nanomedicine, and combination therapy development.

Key Publications

• May RET-positive neuroendocrine lung cancer in pregnancy with placental metastases. (BMJ case reports, 2026, PMID 42173528): "Lung cancer during pregnancy is rare, and placental metastases are exceptionally uncommon."
• May Applying digital technologies for remote care in the real life context: A 3-year experimentation with postoperative lung cancer patients. (Medicine, 2026, PMID 42175423): "Surgery remains the main curative treatment for lung cancer patients."
• May The co-action mechanism of agreement prescription "homotherapy for heteropathy" against esophageal, head and neck cancer, and lung cancer: network pharmacology, bioinformatics analysis, and experimental validation. (Journal of ethnopharmacology, 2026, PMID 41759559): "...in the treatment of esophageal cancer, head and neck cancer and lung cancer..."
• May Wash-Free Digital Detection of Tumor Extracellular Vesicles via Plasmonic Droplet Microfluidics. (ACS sensors, 2026, PMID 42011810): "In 63 clinical samples, PSA- and PSMA-positive EVs yielded AUCs of 0.926 and 0.932 for prostate cancer, respectively, while PD-L1 EVs achieved an AUC of 0.998 for lung cancer."
• May Deep learning multi-omics integration identifies new molecular subtypes of lung cancer. (BioData mining, 2026, PMID 42169010): "Lung cancer, the third most diagnosed cancer in the United States, is driven by a complex combination of molecular alterations, which influence tumor behavior and patient outcomes."
• May CRL2FEM1B uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer. (Molecular cell, 2026, PMID 42086045): "Lung cancers frequently increase iron demand to sustain growth, which makes them vulnerable to ferroptosis."
• Jul Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1‑mediated suppression of the NLRP3 inflammasome. (International journal of molecular medicine, 2026, PMID 42169649): "Lung cancer is one of the most common causes of cancer‑related mortality worldwide, with cisplatin (CP) being a key chemotherapeutic agent."
• May An inhalable microbe-oncolytic virus consortium for lung cancer treatment. (Cell reports. Medicine, 2026, PMID 42034055): "Oncolytic viruses (OVs) represent a promising cancer therapy due to their selective cytotoxicity, yet clinical success in lung cancer is hindered by biological barriers and immunosuppressive microenvironments."
• May Treatment-naïve lung cancer presenting with spinal metastases: a national study of survival, surgery, and the role of predictive biomarkers. (Acta neurochirurgica, 2026, PMID 42154071): "Spinal metastasis as the first manifestation of lung cancer, presents challenges in diagnosis, prognosis, and treatment planning."
• May Promoted Directional Electron Transfer in Pt-Decorated TiO2/Fluorinated Organic Covalent Frameworks for Self-Powered Photoelectrochemical Biosensing. (Analytical chemistry, 2026, PMID 42083754): "This work not only provides a promising tool for the clinical analysis of lung cancer but also offers an effective strategy to improve the directional electron transfer in heterojunction photosystems."